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Paramedics respond to the cardiac arrest of an elderly man in his
home. As they start CPR, the son produces a valid living will with
“no resuscitation” instructions. While they are discussing this with
me at the Medicom base station, another son runs in, tears up the
living will, punches his brother and demands CPR, which was then
restarted.
A young hanging victim with a hopeless brain injury has a cardiac
arrest. I spend more time after responding to the ICU, helping the
mother come to grips with stopping futile CPR than actually doing
“medical care.”
A comatose man with an horrendous brain injury from a gunshot
wound goes to ICU on a ventilator after I had a long discussion with
the mother about organ donation. He ultimately leaves rehab walk
ing and talking.
A 95-year-old man with terminal metastatic cancer comes to the
ER in cardiac arrest. The family demands that “everything be done.”
He spends his final days in ICU comatose with multiple tubes,
machines, etc.
A chronically ill woman with a valid living will has a respiratory
and cardiac arrest at home when her guardian is out shopping. After
CPR, she is on the ventilator in the ER when the family arrives with
all the documents and begs me to stop treatment and let her die at
home. We discontinue everything, they take her home and after
dying at home, the body is returned three hours later for pronounce
ment. Incidentally, I had to ask the police officer to reword his report
that said “patient came to ER with trouble breathing and Dr Holschuh
sent her home to die.”
An elderly woman with smoking-related terminal chronic ob
structive pulmonary disease (COPD) with a valid living will stating
“No ventilator care or intubation,” comes by ambulance in pulmo
nary failure. As she is slipping into unconsciousness, in spite of
initial treatment, from C02 retention, her eyes open and she gasps
“Please save me.” Since she verbally countered her advanced
directive she was immediately intubated and survived that episode.
A 50-year-old man walked alone into the emergency department
up to the nursing desk . He reached out to get attention and collapsed
in cardiac arrest. The crash cart was brought to the spot, he was
defibrillated immediately and about one week later came by the
emergency department to thank the staff for “his life.” We had no
idea who he was or whether he had an advance directive that first
day.
All of these are real cases that happened to me within the last few
years in Hilo. All of them demonstrate how complex end-of-life
decision making can become and the importance of good commu
nication in the process. Whatever one believes about God or a
Creator, man may have been given wisdom and skill by the Creator,
but the Creator didn’t produce the machines or technology. Our
scientific advances have far outstripped our ethical understanding,
good intentions, and common sense. We have a legal system that at
times paralyzes caregivers who attempt to make sound decisions.
And, we are now faced with emerging health delivery models that
some patients fear may someday stop lifesaving treatments for
chronically ill people to save money.
At the June 1996 Annual AMA House of Delegates meeting in
Chicago, a nationally publicized debate took place regarding reso
lutions that asked the AMA to alter its position against physician-
assisted suicide to at least a neutral position. Recent U.S. Circuit
Court of Appeals decisions on the east coast and the 9th Circuit
Court (which includes Hawaii) have essentially removed prohibi
tions on physician-assisted suicide. I got the feeling that many of the
physicians who spoke at the reference committee and on the floor
of the AMA House of Delegates against physician-assisted suicide
might in private discussion feel differently if they felt they had no
voice in terminating their own end of life care.
The U.S. Supreme Court is taking up the circuit court decisions,
and the AMA held to its position against physician-assisted suicide
but some very interesting discussions occurred at the AMA which
lead me to think we must continue to participate in all these
discussions and debates, keeping the patent’s best interests as our
focus.
The activist group “Not Dead Yet” which represents many
disabled individuals, lobbied against physician-assisted suicide at
the AMA meeting. They have been very outspoken nationally and
have called Dr Jack Kevorkian a “serial killer.” I spoke with some
of the protest group members including a very articulate attorney
who is afflicted with some neuromuscular disorder and is wheel
chair bound. She emphasized the very real concern that many of
them have, that a vote to change the AMA position might eventually
lead to overzealous attempts by managed care organizations to end
the lives of severely challenged people. Many of their members are
on home ventilators and fear attempts to discontinue their use.
Some points of debate and discussion which I feel need to be
continued:
(1) Physicians must be sure the discussion on dying is brought up
early on with patients and families. Families and patients must be
counseled that withholding resuscitative efforts and extreme tech
nological support is not equivalent to lack of caring. Quite the
opposite; often not treating a specific terminal condition and ad
dressing the dying process may be the ultimate act of caring.
(2) Physicians must be able to relieve pain and suffering, even if
it hastens death; without fear of legal challenges.
(3) As Dr Stephen Wallach, Honolulu cardiologist, has often
said, we don’t want to damage the existing living will laws, but we
can make it work better without legislation by good communication
with patients and families. When my parents did their first living
wills, my mom wouldn’t have allowed the Heimlich maneuver until
I explained specific details ofresuscitation. For instance, if a patient
has a living will addressing a terminal condition and has an electric
shock or near drowning, do you not treat these reversible condi
tions? It gets back to common sense and good communication.
(4) Physicians must be more proactive with advanced directives.
I see many chronically ill patients in the emergency department who
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have never had living will discussions brought up by their
doctors. I recently had a discussion about advanced directives
with the children of a patient with end stage heart disease, who
thought the discussion of a living will was the equivalent of
contemplating euthanasia. We as a medical association must
help with far reaching public education.
(5) We must bring the discussion of comfort care, quality of
life, and similar issues back into our patient care activities. It is
easier to activate our high tech medical system than to evaluate
the benefits of doing so. A recent New England Journal of
Medicine article on the results of resuscitation on “ER,” “Chi
cago Hope” and “Rescue 911” showed that the public is given an
“unrealistic impression of CPR and its chances for success.”
I’ve actually had people in the Hilo ER assume that arrival by
ambulance at the hospital after a cardiac arrest equals survival.
(6) Physicians must support their patient’s valid advanced
directives. I’m very distressed at seeing family members some
times successfully coerce a treating physician into not following
mom or dad’s advanced directive. In my opinion, this should
include decisions on organ donation. There must be sanctity in
these decisions. We would want nothing less for ourselves.
(7) Because so many people are addressing physician-as
sisted suicide and voluntary euthanasia, I think organized medi
cine must at least be involved in these discussions.
Finally, a George Washington University gerontologist says
she can get intensive care for her patients easier than she can get
them eyeglasses.2
The late Dr David Eckstein, former chair of the medical society
of New Jersey Committee on Biomedical Ethics stated “Do the
best for the patient—not necessarily the most.”3
Dr William Knaus quoted in a People Magazine article “Last
Passage” said: “Death is universal; its never too early to start
talking about it. We need to recognize that dying is one of the
more important things we will do in life. It will be the last
memory we leave to those we love. And if we want to do it better,
than we’re going to have to talk about it.”2
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